SCHEMBL179565

SCHEMBL179565

CCOC(=O)c1c[nH]cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
GABRA1 P14867 4/20 0.41
GABRG2 P18507 4/20 0.41
GABRB3 P28472 4/20 0.41
GABRA5 P31644 4/20 0.41
GABRA3 P34903 4/20 0.41
GABRA2 P47869 4/20 0.41
GABRA4 P48169 4/20 0.41
GABRA6 Q16445 4/20 0.41
GABRP O00591 3/20 0.41
GABRD O14764 3/20 0.41
GABRB1 P18505 3/20 0.41
GABRB2 P47870 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3826623 0.89 KDM4E (0.46) CYP1A2KDM4EALDH1A1KMT2AMAPT
SCHEMBL8646072 0.86 SOAT1 (0.44) CYP1A2KDM4EALDH1A1MEN1KMT2A
SCHEMBL3015836 0.86 ALDH1A1 (0.44) CYP1A2KDM4EALDH1A1MAPTNPC1
SCHEMBL3008544 0.83 LMNA (0.54) CYP1A2KDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL3004724 0.82 LMNA (0.49) CYP1A2KDM4EALDH1A1MAPTNPC1
SCHEMBL3010778 0.80 LMNA (0.50) KDM4EALDH1A1MAPTNPC1RAB9A
SCHEMBL2995184 0.80 LMNA (0.50) KDM4EALDH1A1MAPTNPC1RAB9A
SCHEMBL3006729 0.80 LMNA (0.50) KDM4EALDH1A1MAPTNPC1RAB9A
SCHEMBL13092513 0.80 LMNA (0.50) KDM4EALDH1A1MAPTNPC1RAB9A
SCHEMBL9425655 0.80 LMNA (0.34) CYP1A2KDM4EALDH1A1MAPTGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120192277-A Preparation method of etomidate 仁合益康集团有限公司 2025-06-24 CN claimed
CN-119708058-A Hypoxia activated prodrug derivative and synthesis method thereof 常州大学 2025-03-28 CN claimed
CN-119081799-A Photoresist cleaning solution and preparation method and application thereof 上海盛剑微电子有限公司 2024-12-06 CN claimed
CN-117936174-A High antioxidant network power integrated cable 江苏帝一集团有限公司 2024-04-26 CN claimed
CN-114307254-B Underwater oleophobic/underwater hydrophobic switchable oil-water separation material and preparation method thereof 四川农业大学 2023-10-24 CN claimed
CN-113999542-B Nano composite preparation of disperse dye and preparation method thereof 清华大学 2023-04-18 CN claimed
CN-110078668-B Phenyl imidazole XOR inhibitor, preparation and application 华南理工大学 2023-03-24 CN claimed
CN-115656401-A HPLC detection method for purity of imidazole-4-ethyl formate 武汉海特生物创新医药研究有限公司 2023-01-31 CN claimed
CN-113036174-B Organic framework copolymer supported porous ion-conducting membrane and preparation and application thereof 中国科学院大连化学物理研究所 2022-05-31 CN claimed
CN-114539577-A Mixed matrix membrane based on zeolite imidazole framework material and preparation and application thereof 中国科学院大连化学物理研究所 2022-05-27 CN claimed
CN-216419679-U Crushed aggregates device is used in production of imidazole-4-ethyl formate 南京驰睿生物医药开发有限公司 2022-05-03 CN claimed
CN-114307254-A Oil-water separation material with switchable underwater oleophobic/underwater hydrophobic properties and preparation method thereof 四川农业大学 2022-04-12 CN claimed
CN-113999542-A Nano composite preparation of disperse dye and preparation method thereof 清华大学 2022-02-01 CN claimed
CN-113036174-A Organic framework copolymer supported porous ion-conducting membrane and preparation and application thereof 中国科学院大连化学物理研究所 2021-06-25 CN claimed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
US-9540331-B2 Preparation method of dexmedetomidine intermediate TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) 2017-01-10 US claimed
US-20160272594-A1 PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) 2016-09-22 US claimed
EP-3829559-B1 INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION MERCK SHARP & DOHME LLC (US) 2026-05-13 EP disclosed
US-4292431-A Process for the production of hydroxymethylimidazoles KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 1981-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272594-A1 PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE AVPR2, TET1, TET2 CYP1A2 147/4885KDM4E 855/4885ALDH1A1 852/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR CYP1A2 2553/4885KDM4E 3646/4885ALDH1A1 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.